[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo, AstraZeneca
DS-8201: Data presentation from P2 DESTINY-Breast01 trial (NCT03248492) for (HER2)-positive breast cancer at SABCS (December 11, 2019) (Daiichi Sankyo) - Nov 1, 2019 - Q2 FY 2019 Results 
P2 data
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005454/FY2019Q2_Presentation%20Material.pdf
 
Nov 1, 2019
 
 
9f2102ab-3ecc-4df0-863a-4e2e782cc686.jpg